TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity
- Author(s)
- Shallis, RM; Daver, NG; Altman, JK; Hasserjian, RP; Kantarjian, HM; Platzbecker, U; Santini, V; Wei, AH; Sallman, DA; Zeidan, AM;
- Journal Title
- Cancer
- Publication Type
- epub ahead of print
- Abstract
- TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
- Publisher
- Wiley
- Keywords
- Tp53; acute myeloid leukemia (AML); cutoff; excess blasts; myelodysplastic syndrome (MDS); p53
- Research Division(s)
- Blood Cells And Blood Cancer
- PubMed ID
- 36397669
- Publisher's Version
- https://doi.org/10.1002/cncr.34535
- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2022-12-13 03:13:02
Last Modified: 2022-12-14 01:07:31